🚀 Plus Therapeutics Doubles ReSPECT-LM Clinical Trial Locations in 2024
Plus Therapeutics is proud to announce that we have doubled the number of locations for our ReSPECT-LM clinical trial in 2024, expanding to 6 investigation sites nationwide. This significant expansion allows us to bring cutting-edge treatments to even more patients battling leptomeningeal metastases (LM), a challenging complication of metastatic breast cancer and other cancers.
With our expanded network of sites, we are able to treat more patients and provide access to potentially life-changing therapies.
Full List of ReSPECT-LM Locations & Principal Investigators
As part of our growth, Plus Therapeutics is proud to collaborate with leading medical institutions across the country. For a complete list of ReSPECT-LM clinical trial locations and the Principal Investigators at each site, please visit the following link:
ReSPECT-LM Investigation Sites & Principal Investigators
What’s Next for Plus Therapeutics in 2024 and Beyond?
The expansion of our ReSPECT-LM clinical trial is just one of the many exciting milestones in our ongoing mission to develop innovative treatments for patients with leptomeningeal metastases. We continue to explore new opportunities and partnerships that can further enhance our research and clinical trial capabilities, with the goal of improving outcomes for brain cancer patients.
Stay tuned for more updates as we progress with ReSPECT-LM and other neuro-oncology clinical trials in 2025 and beyond.
Stay Connected with Plus Therapeutics
For more information about our clinical trials, advancements in neuro-oncology, and how to get involved in ReSPECT-LM or other trials, be sure to visit our website and stay updated:
- Visit our website: Plus Therapeutics
- Learn more about the ReSPECT-LM clinical trial: ReSPECT-LM Trial Details
Recent Comments